Daniel C Kirouac
Overview
Explore the profile of Daniel C Kirouac including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
577
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kirouac D, Zmurchok C, Morris D
NPJ Syst Biol Appl
. 2024 Mar;
10(1):31.
PMID: 38499572
Engineered T cells have emerged as highly effective treatments for hematological cancers. Hundreds of clinical programs are underway in efforts to expand the efficacy, safety, and applications of this immuno-therapeutic...
2.
Kirouac D, Zmurchok C, Deyati A, Sicherman J, Bond C, Zandstra P
Nat Biotechnol
. 2023 May;
41(11):1655.
PMID: 37188917
No abstract available.
3.
Kirouac D, Zmurchok C, Deyati A, Sicherman J, Bond C, Zandstra P
Nat Biotechnol
. 2023 Feb;
41(11):1606-1617.
PMID: 36849828
Chimeric antigen receptor T cell (CAR-T) expansion and persistence vary widely among patients and predict both efficacy and toxicity. However, the mechanisms underlying clinical outcomes and patient variability are poorly...
4.
Sayama H, Marcantonio D, Nagashima T, Shimazaki M, Minematsu T, Apgar J, et al.
CPT Pharmacometrics Syst Pharmacol
. 2021 May;
10(8):864-877.
PMID: 34043291
KRAS is a small GTPase family protein that relays extracellular growth signals to cell nucleus. KRAS mutations lead to constitutive proliferation signaling and are prevalent across human cancers. ASP2453 is...
5.
6.
Kirouac D, Cicali B, Schmidt S
CPT Pharmacometrics Syst Pharmacol
. 2019 Jan;
8(4):205-210.
PMID: 30697975
The provision of model code is required for publication in CPT: Pharmacometrics & Systems Pharmacology, enabling quantitative systems pharmacology (QSP) model availability. A searchable repository of published QSP models would...
7.
Kirouac D
CPT Pharmacometrics Syst Pharmacol
. 2018 May;
7(9):547-548.
PMID: 29761661
No abstract available.
8.
Kirouac D, Schaefer G, Chan J, Merchant M, Orr C, Huang S, et al.
NPJ Syst Biol Appl
. 2017 Sep;
3:25.
PMID: 28879057
[This corrects the article DOI: 10.1038/s41540-017-0016-1.].
9.
Kirouac D, Schaefer G, Chan J, Merchant M, Orr C, Huang S, et al.
NPJ Syst Biol Appl
. 2017 Jun;
3:14.
PMID: 28649441
Approximately 10% of colorectal cancers harbor mutations, which constitutively activate the MAPK signaling pathway. We sought to determine whether ERK inhibitor (GDC-0994)-containing regimens may be of clinical benefit to these...
10.
Kirouac D, Du J, Lahdenranta J, Onsum M, Nielsen U, Schoeberl B, et al.
PLoS Comput Biol
. 2016 Apr;
12(4):e1004827.
PMID: 27035903
Understanding the molecular pathways by which oncogenes drive cancerous cell growth, and how dependence on such pathways varies between tumors could be highly valuable for the design of anti-cancer treatment...